DOCSLIB.ORG

Hazardous Chemical Agents (Anti-Neoplastic, Carcinogens, Reproductive Hazards, Neurotoxic)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hazardous Chemical Agents (Anti-Neoplastic, Carcinogens, Reproductive Hazards, Neurotoxic) Hazardous Chemical Agents (anti-neoplastic, carcinogens, reproductive hazards, neurotoxic) Hazard Class / Exposure Controls *refer to Exp. Chemical name CAS: Synonyms Category Hazards Controls tab Notes: Hazardous drug, hormone, Theraputic (NIOSH Table 2 (similar (-)-Epinephrine 51-43-4 Adrenaline neurotransmitter, GHS Cat. 2 Acute toxicity effects)) Chemical review not required, unless used as an experimental drug L(-)-3-(N-Methyl)-α- pyrrolidyl)pyridin, (-)-1-Methyl- (-)-Nicotine 54-11-5 2-(3-pyridyl)pyrrilidine Toxic chemical Acute oral, dermal hazard NIOSH Table 2 (similar effects) (+)-Tetrahydro-4β-hydroxy- N,N,N,5α-tetramethyly-2α- GHS Cat. 1 acute toxicity (+)-Muscarine 2303-35-7 furanmethanaminium chloride hazardous chemical (inhalation), GHS Cat. 2 (dermal) NIOSH Table 2 (similar effects) Isopto Carpine, Sanpilo, GHS Cat. 2 acute toxicity (oral and (+)-Pilocarpine (hydrochloride) 54-71-7 Salageno Hazardous drug inhalation), NIOSH Table 2 (similar effects) 2,2'-bis(8-Formyl-1,6,7- trihydroxy-5-isopropyl-3- (±) Gossypol, from cotton seeds 303-45-7 methylnaphthalene Carcinogen GHS Cat. 2 carcinogen Carcinogen (±)-Nicotine 22083-74-5 Toxic chemical Acute oral, dermal hazard NIOSH Table 2 (similar effects) 1,2-Dimethylhydrazine 306-37-6 Carcinogen Carcinogenicity(Category 1B) Carcinogen IARC Group 2A carcinogen, 1,3 Propanesultone 1120-71-4 Carcinogen / toxic chemical Neurological and behavior effects, Carcinogen TPA, tetradecanoylphorbol acetate, tetradecanoyl phorbol acetate, and phorbol 12- 12-0-tetra-decanoylphorbol-13-acetate 16561-29-8 myristate 13-acetate (PMA) Carcinogen potent tumor promoter UCAR provided list - Carcinogen Diazomethane precursorMNNGN-Methyl-N′- 1-Methyl-3-nitro-1-nitrosoguanidine 70-25-7 nitro-N-nitrosoguanidine Carcinogen Carcinogenicity(Category 1B), Carcinogen *MPTP produces irreversible lesions of the brain dopaminergic system 1-methyl-4phenyl-1,2,3,4- Permanent symptoms of involved in psychomotor functioning with symptoms closely resembling tetrahydropyridine 28289-54-5 MPTP Neurotoxic agent Parkinson's diesease MPTP Parkinson's disease. Refer to detailed exposure control recommendations. 1-Nitrosopyrrolidine 930-55-2 NPYRN-Nitrosopyrrolidine Carcinogen Carcinogenicity(Category 2) Carcinogen 2,3,7,8-tetrachlorodibenz-o-p-dioxin (TCDD) 1746-01-6 TCDD, "Dioxin" Carcinogen IARC Group 1, teratogen, mutagen Carcinogen 9/20/2021 Page 1 of 29 Hazardous Chemical Agents (anti-neoplastic, carcinogens, reproductive hazards, neurotoxic) Hazard Class / Exposure Controls *refer to Exp. Chemical name CAS: Synonyms Category Hazards Controls tab Notes: Germ cell mutagenicity(Category 2), H341Carcinogenicity(Category 1B), H350Reproductive toxicity(Category 2), H361Specific target organ toxicity -repeated 2,4-Dinitrotoluene 121-14-2 Hazardous Drug exposure(Category 2), NIOSH Table 2 (similar effects) Germ cell mutagenicity(Category 2), H341Carcinogenicity(Category 1B), H350Reproductive toxicity(Category 2), H361Specific target organ toxicity -repeated 2,6-Dinitrotoluene 606-20-2 Hazardous Drug exposure(Category 2) NIOSH Table 2 (similar effects) 2-acetylaminofluorene 53-96-3 2-Acetaminofluorene Carcinogen / toxic chemical mutagen, OSHA - Carcinogen UCAR provided list - Carcinogen 1-methyl-6-phenyl-1H- 2-Amino-1-methyl-6-phenylimidazo[4,5- imidazo[4,5-b]pyridin-2-amine; b]pyridine 105650-23-5 PhlP; Carcinogen Carcinogenicity, Category 2 Carcinogen Germ Cell Mutagenicity, Category 2 Carcinogenicity, Category 2 Specific 3-methyl-3H-imidazo[4,5- Target Organ Toxicity (repeated 2-Amino-3-methylimidazo[4,5-f]quinoline 76180-96-6 f]quinolin-2-amine; Hazardous Drug exposure), Category 2 NIOSH Table 2 (similar effects) Germ cell mutagenicity(Category 2), 2-Nitropropane 79-46-9 Carcinogen Carcinogenicity(Category 1B) Carcinogen 3,3',4',4',5 Pentachlorobiphenyl 57465-28-8 PCB 126 Hazardous Chemical STOT RE 2 NIOSH Table 2 (similar effects) Special waste water requirements. Contact UR Env. Compliance / Waste β-aminopropionitrile fumarate Hazardous chemical, potential GHS Cat 1B Reproductive hazard, Management Group. Need to collect any leftover drinking water to dispose of 3-Aminopropionitrile fumarate salt 2079-89-2 salt , BAPN fumarate salt, BAPN anti-neoplastic teratogen NIOSH Table 1 (similar effects) as HazWaste (no cutoff amt) Acute dermal toxicityCategory 2Germ Cell MutagenicityCategory 1BCarcinogenicityCategory 1BSpecific target organ toxicity (single exposure)Category 1Specific 4,4'- target organ toxicity - (repeated 4,4'-Methylenedianiline 101-77-9 Diaminodiphenylmethane Hazardous Drug exposure)Category 2 NIOSH Table 2 (similar effects) 4-Biphenylamine4- Biphenylylamine4- 4-Aminobiphenyl 92-67-1 Phenylaniline Carcinogen Carcinogenicity(Category 1A) Carcinogen 9/20/2021 Page 2 of 29 Hazardous Chemical Agents (anti-neoplastic, carcinogens, reproductive hazards, neurotoxic) Hazard Class / Exposure Controls *refer to Exp. Chemical name CAS: Synonyms Category Hazards Controls tab Notes: 4-Hydroxytamoxifen 68047-06-3 Afimoxifene, 4-OHT, Tamogel Anti-neoplastic drug GHS Cat. 2 Reproductive toxicity NIOSH Table 1 (similar effects) 4-nitroquinoline 1-oxide 56-57-5 4-Nitroquinoline 1-oxide Carcinogen Carcinogenicity (Category 1B), H350 Carcinogen Reproductive toxicity(Category 2), 4-Nonylphenol 104-40-5 p-Nonylphenol Hazardous Chemical H361 NIOSH Table 3 (similar effects) GHS Carcinogen Cat. 2, GHS Acute Toxicity Dermal Cat.2, Acute 4α-Phorbol 12,13-didecanoate 27536-56-7 4α-Phorbol 12-13-dicaprinate Carcinogen Toxicity Inhalation Cat. 1 NISOH Table 2/Carcinogen Special waste water requirements. Contact UR Env. Compliance / Waste BrdU, Broxuridine, GHS Cat. 2 Reproductive hazard, Management Group. Need to collect any leftover drinking water to dispose of 5-bromo-2' deoxyuridine 59-14-3 Bromodeoxyuridine Toxic chemical GHS Cat 1B germ cell mutageb NIOSH Table 3 (similar effects) as HazWaste (no cutoff amt) Special waste water requirements. Contact UR Env. Compliance / Waste Management Group. Need to collect any leftover drinking water to dispose of 5-chloro-2'-deoxyuridine 50-90-8 CldU Toxic chemical GHS Cat. 2 carcinogen Carcinogen as HazWaste (no cutoff amt) Special waste water requirements. Contact UR Env. Compliance / Waste 61135-33-9 EdU GHS Cat. 2 Reproductive hazard, Management Group. Need to collect any leftover drinking water to dispose of 5'-ethynyl-2'-deoxyuridine Toxic chemical GHS Cat 1B germ cell mutageb NIOSH Table 3 (similar effects) as HazWaste (no cutoff amt) FRDU, Floxuridine; FUDR; 2`- Special waste water requirements. Contact UR Env. Compliance / Waste 50-91-9 Deoxy-5-fluorouridine Management Group. Need to collect any leftover drinking water to dispose of 5-Fluoro-2`-deoxyuridine Toxic chemical GHS Cat 2 Germ cell mutagen NIOSH Table 3 (similar effects) as HazWaste (no cutoff amt) 2,4-Dihydroxy-5- 51-21-8 fluoropyrimidine 5-Fluorouracil Carcinogen Carcinogenicity, GHS Cat.2 NIOSH Table 1 Special waste water requirements. Contact UR Env. Compliance / Waste GHS Cat. 2 Reproductive hazard, Management Group. Need to collect any leftover drinking water to dispose of 5-lodo-2'-deoxyuridine 54-42-2 IdU Toxic chemical GHS Cat 2 germ cell mutageb NIOSH Table 3 (similar effects) as HazWaste (no cutoff amt) GHS Cat. 3 carcinogen, GHS Cat. 1B 5α-Dihydrotestosterone 521-18-6 DHT Hazardous drug Reproductive hazard Carcinogen 7,12-dimethylbenzyl(a)anthracene 57-97-6 DMBA Carcinogen GHS Cat 1B carcinogen Carcinogen Reproductive hazard, FDA Special waste water requirements. Contact UR Env. Compliance / Waste pregnancy category C, GHS Management Group. Need to collect any leftover drinking water to dispose of Abacavir 136470-78-5 Dihydrofolliculin Anti-viral, hazardous drug carcinogenicity Cat. 2 NIOSH Table 2 as HazWaste (no cutoff amt) Abiraterone 154229-19-3 17β-Estradiol anti-neoplastic drug Reproductive hazard NIOSH Table 1 GHS Cat. 2 c Carcinogen, GHS Cat. 1B Reproooductive toxicity, GHS Abraxane NA Albumin bound Paclitaxel Anti-neoplastic drug Cat 2 Germ cell mutagen Carcinogen Acetohydroxamic Acid 546-88-3 AHA Hazardous Chemical Reproductive toxicity(Category 1BNIOSH Table 3 (similar effects) Acrylic acid amide, 2- GHS Carcinogen Cat. 1B, GHS Acrylamide 79-06-1 Propenamide Carcinogen, Reproductive Hazard Reproductive toxicity Cat. 2 Carcinogen 9/20/2021 Page 3 of 29 Hazardous Chemical Agents (anti-neoplastic, carcinogens, reproductive hazards, neurotoxic) Hazard Class / Exposure Controls *refer to Exp. Chemical name CAS: Synonyms Category Hazards Controls tab Notes: Highly toxic, mutagen, FDA Actinomycin 50-76-0 D actinomycin Hazardous drug, anti-neoplastic Prgnancy Cat. B NIOSH Table 1 antineoplastic Monoclonal Ado-trastuzumab emtansine 1018448-65-1 Kadcyla Antibodies Reproductive hazard NIOSH Table 1 Afatinib 850140-72-6 Gilotrif anti-neoplastic drug Reproductive hazard NIOSH Table 1 Acute Toxicity: Inhalation, Category 2,3,6aR,9aS-tetrahydro-4- 2 methoxy-1H,11H- Acute Toxicity: Oral, Category 1 cyclopenta[c]furo[3',2':4,5]furo Acute Toxicity: Skin, Category 1 [2,3-h][1]benzopyran1,11- Germ Cell Mutagenicity, Category dione; AFB1; HSDB 3453; NSC 1B Aflatoxin B1 1162-65-8 529592; Hazardous Drug Carcinogenicity, Category 1B NIOSH Table 2 (similar effects) Alefacept 222535-22-0 Amevive Immunosuppresant increased risk of malignancies NIOSH Table 2 Acute Tox.(O) 4: H302Skin Corr. 2: monosodium salt trihydrate H315Eye Damage 1: H318STOT (SE) (1:1:3);Adronat; Fosamax; G- 3: H335 H336Toxic Repro. 2: Alendronate (sodium hydrate) 121268-17-5 704650; MK-21 Hazardous Drug H361STOT (RE) 2: H373 NIOSH Table 2 (similar
Load more

Recommended publications
  • Histone Deacetylase Inhibitors: an Attractive Therapeutic Strategy Against Breast Cancer
    ANTICANCER RESEARCH 37 : 35-46 (2017) doi:10.21873/anticanres.11286 Review Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer CHRISTOS DAMASKOS 1,2* , SERENA VALSAMI 3* , MICHAEL KONTOS 4* , ELEFTHERIOS SPARTALIS 2, THEODOROS KALAMPOKAS 5, EMMANOUIL KALAMPOKAS 6, ANTONIOS ATHANASIOU 4, DEMETRIOS MORIS 7, AFRODITE DASKALOPOULOU 2,8 , SPYRIDON DAVAKIS 4, GERASIMOS TSOUROUFLIS 1, KONSTANTINOS KONTZOGLOU 1, DESPINA PERREA 2, NIKOLAOS NIKITEAS 2 and DIMITRIOS DIMITROULIS 1 1Second Department of Propedeutic Surgery, 4First Department of Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 2N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 3Blood Transfusion Department, Aretaieion Hospital, Medical School, National and Kapodistrian Athens University, Athens, Greece; 5Assisted Conception Unit, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 6Gynaecological Oncology Department, University of Aberdeen, Aberdeen, U.K.; 7Lerner Research Institute, Cleveland Clinic, Cleveland, OH, U.S.A; 8School of Biology, National and Kapodistrian University of Athens, Athens, Greece Abstract. With a lifetime risk estimated to be one in eight in anticipate further clinical benefits of this new class of drugs, industrialized countries, breast cancer is the most frequent
    [Show full text]
  • Phase II Study of Hormone Therapy with Tamoxifen in Patients with Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)
    Phase II study of hormone therapy with tamoxifen in patients with well differentiated neuroendocrine tumors and hormone receptor positive expression (HORMONET) Time of researchers and respective Departments: Rachel Riechelmann (Main Investigador)1, Milton Barros 1, Marcos Camandaroba1,2, Virgilio Souza1,2, Celso Abdon Mello1, Paula Nicole3, Eduardo Nóbrega4, Ludmilla Chinen5, Marina De Brot6, Héber Salvador7. Departaments: 1- Clinical Oncology; 2- postgraduate student; 3- Radiology; 4- Nuclear Medicine; 5-International Research Center (CIPE); 6-Pathologic anatomy; 7- Abdomen Surgery AC Camargo Cancer Center - Brazil Registration Number on Institutional Research Ethics Committee: 2626/18 March,06,2019 Introduction Neuroendocrine tumors (NET) are rare neoplasms, but with increasing incidence and prevalence in the last decades. Although they may manifest in the most diverse tissues, the vast majority of cases will affect organs of the digestive tract and lung. At diagnosis, more than half of the cases present metastatic disease, and among patients with localized disease, up to one-third will have recurrence of the disease. Unfortunately, the minority of patients with metastatic disease are eligible for curative intent.1 Although there are many types of NET, they are often studied together as a group because their cells share common histological findings, have special secretory granules, and the ability to secrete bioactive amines and polypeptide hormones. Approximately 25 percent of the tumors present functional hormonal syndromes (situation of great morbidity for these patients), being the carcinoid syndrome, the most common one. From the molecular point of view, these neoplasias are largely dependent on the activation of the mTOR pathway and neoangiogenesis.2 Another striking feature of neuroendocrine cells is the expression of cell surface hormone receptors whose activation or blockade may exert an important regulatory function.
    [Show full text]
  • Pro-Oxidizing Metabolic Weapons ☆ ⁎ Etelvino J.H
    Comparative Biochemistry and Physiology, Part C 146 (2007) 88–110 www.elsevier.com/locate/cbpc Review The dual face of endogenous α-aminoketones: Pro-oxidizing metabolic weapons ☆ ⁎ Etelvino J.H. Bechara a, , Fernando Dutra b, Vanessa E.S. Cardoso a, Adriano Sartori a, Kelly P.K. Olympio c, Carlos A.A. Penatti d, Avishek Adhikari e, Nilson A. Assunção a a Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes 748, 05508-900, São Paulo, SP, Brazil b Centro de Ciências Biológicas e da Saúde, Universidade Cruzeiro do Sul, São Paulo, SP, Brazil c Faculdade de Saúde Pública, Universidade de São Paulo, São Paulo, SP, Brazil d Department of Physiology, Dartmouth Medical School, Hanover, NH, USA e Department of Biological Sciences, Columbia University, New York, NY, USA Received 31 January 2006; received in revised form 26 June 2006; accepted 6 July 2006 Available online 14 July 2006 Abstract Amino metabolites with potential prooxidant properties, particularly α-aminocarbonyls, are the focus of this review. Among them we emphasize 5-aminolevulinic acid (a heme precursor formed from succinyl–CoA and glycine), aminoacetone (a threonine and glycine metabolite), and hexosamines and hexosimines, formed by Schiff condensation of hexoses with basic amino acid residues of proteins. All these metabolites were shown, in vitro, to undergo enolization and subsequent aerobic oxidation, yielding oxyradicals and highly cyto- and genotoxic α-oxoaldehydes. Their metabolic roles in health and disease are examined here and compared in humans and experimental animals, including rats, quail, and octopus. In the past two decades, we have concentrated on two endogenous α-aminoketones: (i) 5-aminolevulinic acid (ALA), accumulated in acquired (e.g., lead poisoning) and inborn (e.g., intermittent acute porphyria) porphyric disorders, and (ii) aminoacetone (AA), putatively overproduced in diabetes mellitus and cri-du-chat syndrome.
    [Show full text]
  • Comparative Effect of Various HDAC-Inhibitors In-Vitro on T- Cell Lymphoma Cell Lines Alone and in Combination with Conventional Anti-Cancer Drugs
    Comparative effect of Various HDAC-inhibitors in-vitro on T- Cell Lymphoma cell lines alone and in combination with conventional anti-cancer drugs Arshad H. Banday Mentor:Dr. Francisco Hernandez-Illizaliturri Introduction. T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin lymphomas. Historically therapies for these diseases have been borrowed from treatments for other lymphomas. More recently, efforts have be made to identify novel agents for their activity specifically in T-cell lymphomas. A primary example of new agents with specific activity in T-cell lymphomas is the novel class of drug, histone deacetylase inhibitors Vorinostat and romidepsin are currently approved and are in clinical use for the treatment of cutaneous T-cell lymphomas. Intro….. Histones are core structural components of chromatin; DNA is wound around histones, and histones further associate to become and form chromatin. Histone deacetylation inhibitors (HDAC) inhibitors induce accumulation of acetylated histones which leads to relaxation of chromatin structure and promotes access to transcriptional machinery and RNA polymerase HDACi also modify other cancer related proteins. Chromatin Structure Regulates Transcriptional Activity Histone Deacetylase Inhibitors (HDAC Inhibitors) • Cause increased histone acetylation resulting in.. • Uncoiling of chromatin and transcriptional activation of tumor suppressor genes leading to cell cycle arrest and/or apoptosis Currently only Vorinostat is licensed for use in cutaneous T cell lymphoma (CTCL) Genetic
    [Show full text]
  • Multiple Low-Dose Streptozotocin-Induced Diabetes in the Mouse
    Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. R C McEvoy, … , S Sandler, C Hellerström J Clin Invest. 1984;74(3):715-722. https://doi.org/10.1172/JCI111487. Research Article Mice were examined for the presence of splenocytes specifically cytotoxic for a rat insulinoma cell line (RIN) during the induction of diabetes by streptozotocin (SZ) in multiple low doses (Multi-Strep). Cytotoxicity was quantitated by the release of 51Cr from damaged cells. A low but statistically significant level of cytolysis (5%) by splenocytes was first detectable on day 8 after the first dose of SZ. The cytotoxicity reached a maximum of approximately 9% on day 10 and slowly decreased thereafter, becoming undetectable 42 d after SZ was first given. The time course of the in vitro cytotoxic response correlated with the degree of insulitis demonstrable in the pancreata of the Multi-Strep mice. The degree of cytotoxicity after Multi-Strep was related to the number of effector splenocytes to which the target RIN cells were exposed and was comparable to that detectable after immunization by intraperitoneal injection of RIN cells in normal mice. The cytotoxicity was specific for insulin-producing cells; syngeneic, allogeneic, and xenogeneic lymphocytes and lymphoblasts, 3T3 cells, and a human keratinocyte cell line were not specifically lysed by the splenocytes of the Multi- Strep mice. This phenomenon was limited to the Multi-Strep mice. Splenocytes from mice made diabetic by a single, high dose of SZ exhibited a very low level of cytotoxicity against the RIN cells.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Clinical Policy: Pralatrexate (Folotyn)
    Clinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: 02.01.17 Last Review Date: 11.19 Coding Implications Line of Business: HIM*, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Pralatrexate injection (Folotyn®) is a folate analog metabolic inhibitor. ____________ *For Health Insurance Marketplace (HIM), if request is through pharmacy benefit, Folotyn (40 mg/2mL vial) is non-formulary and cannot be approved using these criteria; refer to the formulary exception policy, HIM.PA.103. FDA Approved Indication(s) Folotyn is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Folotyn is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Peripheral T-Cell Lymphoma (must meet all): 1. Diagnosis of PTCL; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Failed prior therapy (see Appendix B for examples); *Prior authorization may be required for prior therapies 5. Request meets one of the following (a or b):* a. Dose does not exceed 30 mg/m2 once weekly for 6 weeks in 7-week cycles; b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). *Prescribed regimen must be FDA-approved or recommended by NCCN.
    [Show full text]
  • Review Article
    REVIEW ARTICLE COLLAGEN METABOLISM COLLAGEN METABOLISM Types of Collagen 228 Structure of Collagen Molecules 230 Synthesis and Processing of Procollagen Polypeptides 232 Transcription and Translation 233 Posttranslational Modifications 233 Extracellular Processing of Procollagen and Collagen Fibrillogenesis 240 Functions of Collagen in Connective rissue 243 Collagen Degradation 245 Regulation of the Metabolism of Collagen 246 Heritable Diseases of Collagen 247 Recessive Dermatosparaxis 248 Recessive Forms of EDS 251 EDS VI 251 EDS VII 252 EDS V 252 Lysyl Oxidase Deficiency in the Mouse 253 X-Linked Cutis Laxa 253 Menke's Kinky Hair Syndrome 253 Homocystinuria 254 EDS IV 254 Dominant Forms of EDS 254 Dominant Collagen Packing Defect I 255 Dominant and Recessive Forms of Osteogenesis Imperfecta 258 Dominant and Recessive Forms of Cutis Laxa 258 The Marfan Syndrome 259 Acquired Diseases and Repair Processes Affecting Collagen 259 Acquired Changes in the Types of Collagen Synthesis 260 Acquired Changes in Amounts of Collagen Synthesized 263 Acquired Changes in Hydroxylation of Proline and Lysine 264 Acquired Changes in Collagen Cross-Links 265 Acquired Defects in Collagen Degradation 267 Conclusion 267 Bibliography 267 Collagen Metabolism A Comparison of Diseases of Collagen and Diseases Affecting Collagen Ronald R. Minor, VMD, PhD COLLAGEN CONSTITUTES approximately one third of the body's total protein, and changes in synthesis and/or degradation of colla- gen occur in nearly every disease process. There are also a number of newly described specific diseases of collagen in both man and domestic animals. Thus, an understanding of the synthesis, deposition, and turnover of collagen is important for the pathologist, the clinician, and the basic scientist alike.
    [Show full text]
  • Hr23b Expression Is a Potential Predictive Biomarker for HDAC Inhibitor Treatment in Mesenchymal Tumours and Is Associated with Response to Vorinostat
    The Journal of Pathology: Clinical Research J Path: Clin Res April 2016; 2: 59–71 Original Article Published online 23 December 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/cjp2.35 HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat Michaela Angelika Ihle,1 Sabine Merkelbach-Bruse,1 Wolfgang Hartmann,1,2 Sebastian Bauer,3 Nancy Ratner,4 Hiroshi Sonobe,5 Jun Nishio,6 Olle Larsson,7 Pierre A˚ man,8 Florence Pedeutour,9 Takahiro Taguchi,10 Eva Wardelmann,1,2 Reinhard Buettner1 and Hans-Ulrich Schildhaus1,11* 1 Institute of Pathology, University Hospital Cologne, Cologne, Germany 2 Gerhard Domagk Institute of Pathology, University Hospital M€unster, M€unster, Germany 3 Sarcoma Center, West German Cancer Center, University of Essen, Essen, Germany 4 US Department of Pediatrics, Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA 5 Department of Laboratory Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima, Japan 6 Faculty of Medicine, Department of Orthopaedic Surgery, Fukuoka University, Fukuoka, Japan 7 Department of Oncology and Pathology, The Karolinska Institute, Stockholm, Sweden 8 Sahlgrenska Cancer Centre, University of Gothenburg, Gothenburg, Sweden 9 Faculty of Medicine, Laboratory of Genetics of Solid Tumours, Institute for Research on Cancer and Aging, Nice, France 10 Division of Human Health & Medical Science, Graduate School of Kuroshio Science, Kochi University Nankoku, Kochi, Japan 11 Institute of Pathology, University Hospital G€ottingen, G€ottingen, Germany *Correspondence to: Hans-Ulrich Schildhaus,Institute of Pathology,University Hospital G€ottingen,Robert-Koch-Strasse40,D-37075G€ottingen, Germany.e-mail: [email protected] Abstract Histone deacetylases (HDAC) are key players in epigenetic regulation of gene expression and HDAC inhibitor (HDACi) treatment seems to be a promising anticancer therapy in many human tumours, including soft tissue sar- comas.
    [Show full text]
  • A Simple Method to Measure Sulfonation in Man Using Paracetamol As Probe Drug Natália Marto 1,2*, Judit Morello1,3, Alexandra M
    www.nature.com/scientificreports OPEN A simple method to measure sulfonation in man using paracetamol as probe drug Natália Marto 1,2*, Judit Morello1,3, Alexandra M. M. Antunes3, Sofa Azeredo4, Emília C. Monteiro1,5 & Sofa A. Pereira1,5 Sulfotransferase enzymes (SULT) catalyse sulfoconjugation of drugs, as well as endogenous mediators, gut microbiota metabolites and environmental xenobiotics. To address the limited evidence on sulfonation activity from clinical research, we developed a clinical metabolic phenotyping method using paracetamol as a probe substrate. Our aim was to estimate sulfonation capability of phenolic compounds and study its intraindividual variability in man. A total of 36 healthy adult volunteers (12 men, 12 women and 12 women on oral contraceptives) received paracetamol in a 1 g-tablet formulation on three separate occasions. Paracetamol and its metabolites were measured in plasma and spot urine samples using liquid chromatography-high resolution mass spectrometry. A metabolic ratio (Paracetamol Sulfonation Index—PSI) was used to estimate phenol SULT activity. PSI showed low intraindividual variability, with a good correlation between values in plasma and spot urine samples. Urinary PSI was independent of factors not related to SULT activity, such as urine pH or eGFR. Gender and oral contraceptive intake had no impact on PSI. Our SULT phenotyping method is a simple non-invasive procedure requiring urine spot samples, using the safe and convenient drug paracetamol as a probe substrate, and with low intraindividual coefcient of variation. Although it will not give us mechanistic information, it will provide us an empirical measure of an individual’s sulfonator status. To the best of our knowledge, our method provides the frst standardised in vivo empirical measure of an individual’s phenol sulfonation capability and of its intraindividual variability.
    [Show full text]